Wegovy

Wegovy (semaglutide) is a prescription-only injectable medication approved by the MHRA for the management of overweight and obesity in adults. It works by mimicking the action of GLP-1, a hormone that regulates appetite and food intake. Wegovy helps reduce hunger, promoting gradual and sustainable weight loss. This treatment is designed for adults with a BMI of 27 or higher with weight-related health conditions, or for those with a BMI of 30 or higher. By lowering appetite and improving metabolic function, Wegovy supports weight management, making it easier to adopt healthier eating habits and maintain long-term weight loss. Clinical trials have shown that Wegovy can lead to significant weight loss, with patients losing an average of 15-20% of their body weight. In the STEP program, 86% of participants achieved at least 5% weight loss, and 67% achieved 10% or more. Wegovy is available in multiple dosage strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. Patients begin with a low dose and gradually increase over time, allowing the body to adjust and minimizing side effects. At UK Weight Loss, we provide comprehensive support, including initial consultations, regular follow-up appointments, and ongoing monitoring to ensure your progress and adjust your treatment as necessary.